SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

4/10/23 9:37:13 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RUBY alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.6 RUBIUS THERAPEUTICS INC COMMON STOCK Cusip #78116T103 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #78116T103 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 298,019 Item 6: 0 Item 7: 298,019 Item 8: 0 Item 9: 298,019 Item 11: 0.329% Item 12: HC Cusip #78116T103 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 298,019 Item 8: 0 Item 9: 298,019 Item 11: 0.329% Item 12: IN Item 1(a). Name of Issuer: RUBIUS THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 124 WASHINGTON STREET, SUITE 101, C/O VERDOLINO & LOWEY, P.C. FOXBORO, MA 02035 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 78116T103 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 298,019 (b) Percent of Class: 0.329% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 298,019 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of RUBIUS THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of RUBIUS THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. April 6, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on April 6, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of RUBIUS THERAPEUTICS INC at March 31, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $RUBY alert in real time by email

Date	Price Target	Rating	Analyst
9/13/2022		Buy → Neutral	Guggenheim
2/25/2022	$14.00 → $5.00	Market Perform	SVB Leerink
11/9/2021	$20.00 → $14.00	Market Perform	SVB Leerink
10/19/2021	$25.00 → $22.00	Equal-Weight	Morgan Stanley

SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $RUBY

$RUBY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Appelhans Dannielle sold $1,323 worth of shares (10,385 units at $0.13), closing all direct ownership in the company

SEC Form 4: Cagnoni Pablo J sold $2,112 worth of shares (8,448 units at $0.25), decreasing direct ownership by 11% to 66,082 units to cover withholding tax

SEC Form 4: Appelhans Dannielle converted options into 7,500 shares and sold $970 worth of shares (3,878 units at $0.25), increasing direct ownership by 54% to 10,385 units to satisfy withholding tax

$RUBY Leadership Updates

Live Leadership Updates

Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform

HotSpot Therapeutics Appoints Jose Carmona to Board of Directors

$RUBY Financials

Live finance-specific insights

$RUBY Press Releases

Fastest customizable press release news feed in the world

Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

Rubius Therapeutics to Announce First Quarter 2022 Financial Results

Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform

Cellarity Announces Close of $121 Million Series C Financing

$RUBY Large Ownership Changes

This live feed shows all institutional transactions in real time.